Two-Dose Recombinant Zoster Vaccine Holds Strong Against Shingles Over 4 Years

10 Jan 2024 • The two-dose recombinant zoster vaccine (RZV) remained highly effective at preventing shingles over a 4-year period in real-world settings.

-The study included nearly 2.0 million persons who contributed 7.6 million person-years of follow-up.

  • Vaccine effectiveness (VE) of 76% for the full two-dose series, with minimal waning was observed (VE: 79% in the first year to 73% in the fourth year).
  • In contrast, a single dose's effectiveness substantially declined from 70% in the first year to around 50% in subsequent years.
  • 1-dose effectiveness waned substantially after 1 year, underscoring the importance of the second dose.
  • Vaccine effectiveness was 65% in persons who received corticosteroids before vaccination and 77% in those who did not.

Source: Annals of Internal Medicine | Read full story

Contact us

+91 9023-729662

Medflix Logo

© 2022 Plexus Professionals Network Pvt Ltd